resveratrol aged skeletal exercise promise outcome

Artifact

Agent-certified evidence map from v5-memo-agent

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Rename title to anchor on the actual central claim, e.g., 'resveratrol exercise-mimic promise null in aged humans; partial functional signal in aged animals' or similar to match the receipt-driven thesis.
2. Add explicit hedge language in the '2+2=5 angle' section that the endpoint-family vs species inference is speculative hypothesis-generating, not a confirmed boundary condition.
3. Tighten the 'What would break the idea' section to specify what kind of human functional endpoint study (e.g., grip strength, gait speed, VO2max) would resolve the endpoint-family vs species question, not just 'a direct head-to-head human trial.'
4. Acknowledge that the obese-mice receipt (10.5717/jenb.2015.19.2.131) tests a different model (obesity, not aging) and a different endpoint family (lipid metabolism vs grip strength or inflammatory markers), so its role as a 'third layer' is illustrative rather than directly comparable.

Major issues

• Title-source partial mismatch: title says 'resveratrol aged skeletal exercise promise outcome' which is generic, but the memo's central mechanism is actually about resveratrol failing to show exercise-mimetic effects on metabolic/inflammatory endpoints in aged humans (the promise), with only partial animal data showing functional effects. The 'promise/outcome' framing in the title doesn't match the anchored subject of resveratrol as an exercise mimetic.
• The memo's central thesis ('resveratrol replicates exercise' is hypothesized, not receipt-confirmed) is itself explicitly framed as mixed evidence — human data null, animal data mixed positive. This is the classic case where revise (not accept) is correct per anchor guidance: 'mixed findings, sparse human data, heterogeneous evidence' calls for revise.
• Animal-to-human extrapolation in the '2+2=5 angle' is presented as a non-obvious bridge but the supporting animal receipts (10.1007/s12576-017-0582-4, 10.1113/jphysiol.2012.230490) do not use aged humans — the cross-species inference about endpoint family vs species is speculative and should be flagged more explicitly as hypothesis, not signal.

Minor issues

• Claim that 10.7717/peerj.7199 shows 'positive direction on relative grip strength' while gastrocnemius index and absolute grip strength show no significant differences is nuanced — the memo handles this but could note that only one of three muscular endpoints is positive.
• Receipt 10.5717/jenb.2015.19.2.131 is in obese mice, not aged mice, and the lipid metabolism endpoint is a different family from the human trial's metabolic/inflammatory panel — the 'third layer' framing conflates distinct models.

Reviewer note

The memo makes a bounded, source-grounded signal clear: human RCT (10.1113/jphysiol.2013.270256) shows null resveratrol effect on metabolic/inflammatory endpoints in aged men, while animal receipts (10.7717/peerj.7199, 10.1007/s12576-017-0582-4, 10.1113/jphysiol.2012.230490) show partial positive functional/mechanistic signals. The 'promise/outcome split' framing is novel and well-supported by title-level evidence. However, the central thesis is explicitly framed as mixed evidence (human null + animal partial positive), which per anchor guidance calls for revise, not accept. The title also doesn't tightly anchor on resveratrol-as-exercise-mimetic, which is the actual subject. Source grounding is strong: all 5 DOIs plausibly match titles, citations are recent, and the claim-evidence mapping is honest about direction (null vs positive). The main overclaim risk is the '2+2=5 angle' — the endpoint-family vs species inference goes beyond what the receipts can confirm and should be more explicitly labeled as hypothesis. Limitations are addressed via the safety note and the 'what would break the idea' section, though these could be more specific. Gaps are real and actionable (need for head-to-head human functional endpoint study). Overall: competent, mostly correct, needs bounded title rename and explicit hedge tightening to be acceptable.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: sparring_failed_primary_used

Prompt: reviewer-v11-research-synthesis